| Literature DB >> 25018669 |
Karlheinz Mann1, Eric Edsinger2.
Abstract
BACKGROUND: Although the importance of proteins of the biomineral organic matrix and their posttranslational modifications for biomineralization is generally recognized, the number of published matrix proteomes is still small. This is mostly due to the lack of comprehensive sequence databases, usually derived from genomic sequencing projects. However, in-depth mass spectrometry-based proteomic analysis, which critically depends on high-quality sequence databases, is a very fast tool to identify candidates for functional biomineral matrix proteins and their posttranslational modifications. Identification of such candidate proteins is facilitated by at least approximate quantitation of the identified proteins, because the most abundant ones may also be the most interesting candidates for further functional analysis.Entities:
Year: 2014 PMID: 25018669 PMCID: PMC4094399 DOI: 10.1186/1477-5956-12-28
Source DB: PubMed Journal: Proteome Sci ISSN: 1477-5956 Impact factor: 2.480
Fifty-seven proteins with an individual percentage of equal to or larger than 0.1% constitute 98% of the total identified proteome
| Lotgi1|162078 DGLSP_LOTGI2 | 16.71 | ++ | |
| Lotgi1|2354971 PRP1_LOTGI2 | 12.28 | (+) | |
| Lotgi1|2391741 GMP_LOTGI2 | 9.14 | | |
| Lotgi1|239214 GSP1_LOTGI2 | 6.82 | (+) | |
| Lotgi1|2328171 PLSP2_LOTGI2 | 6.80 | ++ | |
| Lotgi1|2391701 GRP_LOTGI2 | 5.91 | | |
| Lotgi1|2388311 USP5_LOTGI2 | 5.11 | | |
| Lotgi1|2334201 CCD1_LOTGI2 | 3.49 | ++ | |
| Lotgi1|1406601 Lotgi1|1731392 | 2.81 | | |
| Lotgi1|2348851 USP13_LOTGI2 | 2.13 | | |
| Lotgi1|2310461 USP16_LOTGI2 | 2.01 | | |
| Lotgi1|2305101 PRP2_LOTGI2 | 1.67 | | |
| Lotgi1|2313111 GEPRP_LOTGI2 | 1.45 | + | |
| Lotgi1|1732001 MRP_LOTGI2 | 1.43 | | |
| Lotgi1|2385261 USP26_LOTGI2 | 1.42 | + | |
| Lotgi1|2282681 USP8_LOTGI2 | 1.22 | + | |
| Lotgi1|1581131 | 1.19 | | |
| Lotgi1|166131 Lotgi1|1016111 | 1.09 | + | |
| Lotgi1|2332001 SCP2_LOTGI2 | 0.97 | | |
| Lotgi1|2380821 CAH1_LOTGI2 | 0.96 | | |
| Lotgi1|2391881 CAH2_LOTGI2 | 0.88 | | |
| Lotgi1|2310091 | 0.87 | | |
| Lotgi1|1731381,2 | 0.87 | | |
| Lotgi1|1740651 | 0.81 | | |
| Lotgi1|2361831 USP4_LOTGI2 | 0.77 | | |
| Lotgi1|2356211 GTRP_LOTGI2 | 0.71 | | |
| aa151-448 96% identity to | Lotgi1|234936 CCD2_LOTGI2 | 0.67 | |
| Lotgi1|2391251 Lotgi1|226725 | 0.66 | | |
| Lotgi1|1749201,2 | 0.64 | + | |
| Lotgi1|1407861 Lotgi1|225855 | 0.61 | | |
| Lotgi1|2331991 SCP1_LOTGI2 | 0.53 | | |
| Lotgi1|2394471 Lotgi1|175200 | 0.47 | | |
| Lotgi1|239121 Lotgi1|201802 PWAPL_LOTGI2 | 0.39 | | |
| Lotgi1|2343871 | 0.38 | | |
| Lotgi1|2379961 Lotgi1|172116 PRP3_LOTGI2 | 0.34 | | |
| Lotgi1|2355481 ELDP1_LOTIA2 | 0.27 | | |
| Lotgi1|2328181 Lotgi1|99809 PLSP3_LOTGI2 | 0.26 | | |
| Lotgi1|1636371,2 | 0.25 | | |
| Lotgi1|2333971 Lotgi1|163339 | 0.24 | | |
| Lotgi1|2229791 Lotgi1|169679 PPI_LOTGI2 | 0.24 | | |
| Lotgi1|2308541 Lotgi1|99757 | 0.23 | | |
| Lotgi1|1593311 | 0.22 | | |
| Lotgi1|1740031 | 0.22 | | |
| Lotgi1|2356101,2 | 0.20 | | |
| Lotgi1|167423 ELDP2_LOTGI2 | 0.19 | | |
| Lotgi1|2375101 Lotgi1|171086 | 0.16 | | |
| Lotgi1|2267261 Lotgi1|2391292 | 0.16 | + | |
| Lotgi1|2282641 | 0.15 | | |
| Lotgi1|2348841 Lotgi1|166202 | 0.14 | | |
| Lotgi1|2383581 ASRP_LOTGI2 | 0.14 | + | |
| Lotgi1|1710841 | 0.11 | + | |
| Lotgi1|2389701 PLSLP_LOTGI2 | 0.11 | | |
| Lotgi1|1583161 | 0.10 | | |
| Lotgi1|2050301 Lotgi1|237594 | 0.10 | | |
| Lotgi1|1540201 | 0.10 | ++ | |
| Lotgi1|2366901 USP22_LOTGI2 | 0.10 | | |
| Lotgi1|2395741,2 | 0.10 |
+, less than three peptides phosphorylated; ++, three or more phosphopeptides; (+), not confirmed with phosphopeptide-enriched samples. DS, predicted disordered structure. 1, previously identified by Mann et al., 2012 [17]; 2, previously identified by Marie et al., 2013 [18].
Figure 1Alignment of EFCB2 to similar sequences. Sequences covered by MS/MS-sequenced peptides are shown in red. Slashes in the sequence of Lotgi1|239519 indicate an insert between signal peptide and the EFCB2-like sequence that does not occur in the other entries. All shown entries were part of protein groups containing other similar sequences due to the high redundancy of the AllModels database.
Figure 2An example of different partially occupied phospho sites in one sequence. This peptide occurs in the sequence of DGLSP/B3A0P1/Lotgi1|162078 (Aspartate-, glycine-, lysine- and serine-rich protein, aa324-335). A, peptide variant with phosphotyrosine identified by an uninterrupted series of y-ions for the rest of the sequence and the very intense diagnostic pY immonium ion at m/z 216.042. Expert annotations [29] were omitted, except for the major peak at m/z 120.0809 (phenylalanine immonium ion), to keep the spectrum clear. The doubly charged peptide ion was measured with a mass error of −0.014 ppm. PEP and phosphphorylation site localization probability were calculated by MaxQuant to be 8.96e-93 and 0.999. B, this time S4 was determined as the phosphorylation site in an uninterrupted series of y-ions from y1 to y11. The mass error was −0.490 ppm, PEP was 1.16e-54 and the localization probability was 1.00. Major peaks at m/z 120.0809 and 136.0756 were annotated by the MaxQuant Expert system as the phenylalanine immonium ion and the a1-ion. A major peak at m/z 192.1016 was not annotated. Expert annotations of most of the minor peaks are omitted for clarity. C, a third phosphorylation site at S8 was detected with a localization probability of 1.00 in still another variant of this peptide measured with a mass error of 0.531 ppm and with a PEP of 3.28e-164. Again, most expert annotations are omitted. *, ions showing a loss of H3PO4 from phosphoserine. Y-ions are shown in red, b-ions are shown in blue, b-or y-ions with a loss of ammonia or water are in orange, the a2 ion is shown in light blue, black identifies ions without annotation unless the annotation is shown on top of the peak.